Literature DB >> 23523416

Random biopsies during surveillance colonoscopy increase dysplasia detection in patients with primary sclerosing cholangitis and ulcerative colitis.

Udayakumar Navaneethan1, Gursimran Kochhar, Preethi G K Venkatesh, Ana E Bennett, Maged Rizk, Bo Shen, Ravi P Kiran.   

Abstract

BACKGROUND AND AIM: Patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) are at increased risk of colon dysplasia. The role of random vs. target biopsies in these patients has not been investigated. Our aim was to evaluate the yield and clinical impact of random biopsies during surveillance colonoscopies in patients with PSC-UC.
METHODS: Data from 71 patients (267 colonoscopies) with PSC and UC, who underwent surveillance colonoscopies and followed-up from 2001 to 2011 was obtained. Colonoscopy and pathology reports were reviewed to assess the yield of random biopsies.
RESULTS: A total of 3975 (median 12) random biopsies were taken during surveillance colonoscopies. Overall, neoplasia was detected in 22 colonoscopies (16 patients): in 8 colonoscopies (36.4%) by targeted biopsies only and in 4 (18.2%) by both targeted and random biopsies. Neoplasia was detected in random biopsies only in 10 (45.5%) colonoscopies in 8 patients. On multivariate analysis, duration of UC (Odds ratio [OR]=1.40; 95% confidence interval [CI], 1.08-1.81; P=0.01), number of random biopsies (per increase by 8) (OR=1.64; 95% CI, 1.18-2.28; P=0.003) and target biopsies during colonoscopy (OR=9.08; 95% CI, 3.18-26.0; P<0.001) independently predicted the presence of dysplasia; endoscopic features of prior inflammation did not.
CONCLUSIONS: Random biopsies significantly increase the yield of dysplasia in patients with PSC and UC even in the absence of endoscopic features of prior inflammation and significantly impact clinical outcomes.
Copyright © 2013 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  BMI; CD; CRC; Colonoscopy; Crohn's disease; Dysplasia; HGD; IBD; Inflammatory bowel disease; LGD; Random biopsies; UC; Ulcerative colitis; aOR; adjusted odds ratio; body mass index; colorectal cancer; high grade dysplasia; inflammatory bowel disease; low grade dysplasia; ulcerative colitis

Mesh:

Year:  2013        PMID: 23523416     DOI: 10.1016/j.crohns.2013.02.009

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  9 in total

1.  Chromoendoscopy and Dysplasia Surveillance in Inflammatory Bowel Disease: Past, Present, and Future.

Authors:  Steven Naymagon; Thomas A Ullman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-05

Review 2.  Colorectal cancer risk of flat low-grade dysplasia in inflammatory bowel disease: a systematic review and proportion meta-analysis.

Authors:  Sara Lauricella; Silvia Fabris; Patricia Sylla
Journal:  Surg Endosc       Date:  2022-08-03       Impact factor: 3.453

3.  Current and Future Status for Evaluation of Dysplasia and Carcinoma in IBD.

Authors:  Joann Kwah; Francis A Farraye
Journal:  Curr Treat Options Gastroenterol       Date:  2014-03

4.  Dysplasia Surveillance in Inflammatory Bowel Disease: A Cohort Study.

Authors:  Sofia Saraiva; Isadora Rosa; Joana Moleiro; João Pereira da Silva; Ricardo Fonseca; António Dias Pereira
Journal:  GE Port J Gastroenterol       Date:  2020-10-19

Review 5.  Hepatobiliary manifestations of ulcerative colitis: an example of gut-liver crosstalk.

Authors:  Udayakumar Navaneethan
Journal:  Gastroenterol Rep (Oxf)       Date:  2014-06-20

Review 6.  Early detection of ulcerative colitis-associated colorectal cancer.

Authors:  Yu Zhen; Chengxin Luo; Hu Zhang
Journal:  Gastroenterol Rep (Oxf)       Date:  2018-05-14

Review 7.  Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention.

Authors:  Wenqian Li; Tiantian Zhao; Dacheng Wu; Jiajia Li; Mei Wang; Yunyun Sun; Sicong Hou
Journal:  Curr Oncol       Date:  2022-08-25       Impact factor: 3.109

8.  Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance.

Authors:  Anne B Hu; Kristin E Burke; Bharati Kochar; Ashwin N Ananthakrishnan
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325

Review 9.  Screening and surveillance methods for dysplasia in inflammatory bowel disease patients: Where do we stand?

Authors:  Michail Galanopoulos; Emmanouela Tsoukali; Filippos Gkeros; Marina Vraka; Georgios Karampekos; Gerassimos J Matzaris
Journal:  World J Gastrointest Endosc       Date:  2018-10-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.